Skip to main content
. 2017 Jul 20;8(65):108522–108533. doi: 10.18632/oncotarget.19411

Figure 4. EGFR-mutant NSCLCs with the BIM deletion are more viable in high doses of erlotinib than that without BIM deletion counterparts.

Figure 4

(A). EGFR-mutant NSCLC cell lines HCC827, RERF-Ad-A2, HCC2279 and PC3 were exposed to different doses of erlotinib for 72 hours, and the cell survival was assessed. Results are given as mean ± SD (n = 3). (B). The cell relative viability was significantly increased by treated with BIM shRNA#1 and shRNA#2 in BIM wide-type cell lines HCC827 and RERF-Ad-A2; (C). The cell relative viability was significantly reduced in BIM deletion cell lines HCC2279 and PC3 which treated with BIM over-expression vector.